Miguel-Angel Perales, MD
Chief, Adult Bone Marrow Transplant Service
Bone Marrow Transplantation; Immunotherapy and Cancer Vaccines; CAR T Cell Therapy
New Patient Appointments
Scheduling a visit is easy. Click below or call us to get started.
Dr. Perales accepts the following list of insurance providers. Select your insurance provider to see more details.
Memorial Sloan Kettering is an in-network provider with Aetna HMO, POS, and PPO plans. Aetna does not include us in any of the plans you can purchase through the insurance exchanges or through Medicare. Please ask your insurance if you need a one-time referral. MSK has an agreement with the Aetna Transplant Program for all Aetna's commercial products.
Memorial Sloan Kettering is a designated Blue Distinction Center for bone marrow transplant and CAR-T.
We understand that there may be many complexities involved with insurance coverage purchased through the health exchange network of the Affordable Care Act. We’re here to help. If you have questions about how your care will be covered by an insurance provider, or need help navigating a change in coverage, please call us at 646-227-3378; if you are not a resident of New York, you can call us at 866-248-1274. Our team is here to listen to your concerns and assist you in any way we can. We want our care to be as accessible and affordable for as many people as possible.
Memorial Sloan Kettering is an in-network provider with CIGNA's HMO, POS, and PPO plans. CIGNA does not include us in any of the plans you can buy through the insurance exchanges.
- If you are a New York State resident: Please ask your insurance if you need a one-time referral.
- If you live outside of New York State: Please ask your insurance if you have in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with EmblemHealth’s PPO, EPO, POS, HMO plans. EmblemHealth includes GHI, HIP, Vytra, and ConnecticCare (in NYS Only). You must bring a referral from your Emblem primary care doctor to your first appointment. In-network participation exceptions include:
- Emblem’s HIP Commercial Millennium, Select Care and Enhanced Care Prime networks is not in-network with Memorial Sloan Kettering.
- Please call Emblem to confirm if your specific plan is in-network.
For information regarding Memorial Sloan Kettering’s participation with Emblem’s Medicare Advantage Plans, please refer to the Medicare & Medicaid page
Memorial Sloan Kettering is an in-network provider with Empire Blue Cross Blue Shield (Wellpoint) of New York Indemnity, HMO, EPO, PPO, POS and Medicare Advantage plans, with the following exceptions:
- Empire Blue Cross Blue Shield does not include us in any of the plans you can buy through the insurance exchanges.
- Please call Empire BCBS to confirm if your specific plan is in-network with Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with HealthFirst’s commercial products; these commercial products are not purchased on the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with HealthSmart’s Accel, HSPC, and HPO networks.
For our NJ locations, Memorial Sloan Kettering is an in-network provider with most Horizon Blue Cross Blue Shield of New Jersey plans for individuals, families, and small businesses. Horizon members with Blue Card Access (there would be a suitcase logo on the front of the card) may have access to our NY locations. Please call Horizon to confirm if your plan is in-network in NY.
Memorial Sloan Kettering is a designated Center of Excellence by Humana.
Memorial Sloan Kettering is a designated Center of Excellence by Interlink Health Services.
Memorial Sloan Kettering is a designated Center of Excellence by Lifetrac.
Memorial Sloan Kettering is an in-network provider for all MagnaCare health plans except those products you can buy through the insurance exchanges.
For information about Medicare and Medicaid, please visit this page
Memorial Sloan Kettering is an in-network provider with some Multiplan/Beech Street/PHCS plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is a designated Center of Excellence by Multiplan.
If you are covered by more than one insurance plan, you will want to determine your benefits from both plans. First, you need to determine which one is your primary insurance provider by contacting your employee benefits office or your insurance carriers. After you find out which is your primary insurance provider, you should then contact your insurance carrier to determine if you have access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with some MVP plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider for New York State employees who have enrolled in UnitedHealthcare's Cancer Resource Services. If you have the Empire Plan, you should call Cancer Resources Services at 866-936-6002 to verify and enroll in this coverage.
Memorial Sloan Kettering is in-network with Oscar’s Circle Plus Network, a part of its Small Group Broad line that is offered only to select small business groups. Oscar does not include Memorial Sloan Kettering as an in-network provider for any of its individual plans. Please confirm eligibility with your insurance carrier.
Most Blue Cross Blue Shield plans include Memorial Sloan Kettering as an in-network provider. Contact your insurance company to confirm if Memorial Sloan Kettering is in-network.
We have agreements with several insurance companies that may provide additional coverage for cancer patients. These benefit programs include:
- AXA Assistance USA
- Beech Street
- Integrated Health Plans
- National Health Administrators
- National Preferred Provider Network
- UnitedHealthcare's Cancer Resource Services
- United Resource Network
- Veterans Choice Program
Memorial Sloan Kettering is an in-network provider with Oxford’s Freedom and Liberty plans as well as the Metro Plan (which is only offered to small business groups and no longer offered as individual plans). Please confirm with your insurance if you need a one-time referral. Note: Oxford’s Medicare Managed Care plan — Secure Horizon — does not include Memorial Sloan Kettering as an in-network provider. Oxford does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with the World Trade Center Health Program.
Memorial Sloan Kettering is an in-network provider with QualCare's PPO and HMO/POS network.
Memorial Sloan Kettering is a designated Center of Excellence by Specialty Care Management.
Hospital and physician services may be covered by TRICARE. Please call your TRICARE plan to confirm coverage at Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with UnitedHealthCare's HMO, POS, and PPO plans. Please confirm with your insurance if a one-time referral is needed.
UnitedHealthCare's Medicare Managed Care plan does not include Memorial Sloan Kettering as an in-network provider.
United does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is a designated Center of Excellence by UnitedHealthcare.
Contact and Location
Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offer many services, including screening, chemotherapy, and medical testing.
MD, Free University of Brussels
Internal Medicine - Tufts-New England Medical Center
Medical Oncology/Hematology - Memorial Sloan Kettering Cancer Center; Medicine - Weill Cornell Medical College
Internal Medicine, Medical Oncology
I am a board-certified medical oncologist with expertise in donor-derived hematopoietic (blood-forming) stem cell transplantation. Hematopoietic stem cells from a donor other than the patient can cure many patients who have diseases of the blood and bone marrow, including leukemias and lymphomas. The donor stem cells can come from different sources (related or unrelated donors, and bone marrow, peripheral blood, or umbilical cord blood units) and can be modified in different ways before transplantation to enhance their effectiveness.
Along with colleagues here, I am participating in a number of studies designed to improve outcomes in patients undergoing stem cell transplantation, including finding ways to lower the risk of complications, relapse, and graft-versus-host disease. In particular, I am leading a clinical trial in patients who have advanced Hodgkin lymphoma; the goal of the trial is to determine the safest way to perform a transplant using stem cells from a donor in patients with relapsed Hodgkin lymphoma.
I also conduct translational clinical research investigating new ways to enhance the recovery of the immune system after a transplant and ways to help the immune system fight hematologic malignancies. My colleagues and I are investigating new agents such as interleukin-7 and KGF to enhance immune recovery, as well as new approaches to generate specialized T cells that will specifically target hematologic malignancies.
My practice consists of patients with a variety of hematologic malignancies who are in need of an allogeneic transplant, including patients with acute myelogenous leukemia, acute lymphoblastic leukemia, myelodysplastic syndromes, chronic lymphocytic leukemia, non-Hodgkin lymphoma, and Hodgkin lymphoma. The goal of my practice and clinical research is to be able to offer every patient in need of a transplant the opportunity to undergo this potentially curative therapy.
- Clinical Trials Investigated by Dr. Perales
- A Phase I Study of NKTR-255 in People with Multiple Myeloma or Non-Hodgkin Lymphoma
- A Phase II Study of MB-CART2019.1 CAR T-Cell Therapy in People with Diffuse Large B-Cell Lymphoma
- Clinical Trials Co-Investigated by Dr. Perales
- A Phase I Study of CC-97540 CAR T-Cell Therapy in People with Relapsed or Persistent B-Cell Non-Hodgkin Lymphoma
- A Phase I/II Study of SMART101 in Children and Adults with Acute Leukemia Who Receive a T-Cell Depleted Stem Cell Transplant from a Donor
- A Phase IB Study of SER-155 in Adults Who Will Receive a Stem Cell Transplant and Are at Risk of Infections and Graft-versus-Host Disease
- A Phase II Study of JCAR017 in People with Recurrent or Persistent Follicular Lymphoma or Marginal Zone Lymphoma
- A Phase II Study of Mismatched Unrelated Donor Stem Cell Transplantation in People with Blood Cancers
- A Phase II Study of Ruxolitinib Before, During, and After a Stem Cell Transplant for Myelofibrosis
- A Phase III Study of Alpha 1-Antitrypsin plus Corticosteroids versus Corticosteroids Alone to Treat High-Risk Acute Graft-versus-Host Disease after an Allogeneic Stem Cell Transplant
- A Study of T-Cell Depleted Allogeneic Stem Cell Transplantation Using a Low-Intensity Conditioning for Patients with Myeloid Cancers and Aplastic Anemia
- Pilot Study of Homebound Stem Cell Transplantation for Patients with Multiple Myeloma
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Research and Publications
Visit PubMed for a full listing of Dr. Perales’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Miguel-Angel Perales discloses the following relationships and financial interests:
Provision of Services
Ownership / Equity Interests; Provision of Services (uncompensated)
Provision of Services
Ownership / Equity Interests; Provision of Services
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.